공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

중추신경계 치료제 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년)

Central Nervous System Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 1008461
페이지 정보 영문
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)

중추신경계 치료제 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년) Central Nervous System Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

중추신경계(CNS) 치료제 시장은 2021-2026년의 예측 기간 중 5.9% 정도의 CAGR에 달할 것으로 예측됩니다.

중추신경계 질환을 앓고 있는 환자 수의 증가는 중추신경계 치료제 시장의 성장에 기여하는 중요한 요인일 가능성이 있습니다. WHO에 따르면 뇌졸중과 알츠하이머병은 2019년에 세계에서 2번째와 7번째로 많은 사인이었습니다. 또한 제네릭 의약품의 증가에 의해 신경계 의약품의 저중소득국으로의 침투가 촉진되며 적정 가격이 될 것으로 예상됩니다. 또한 나노입자 등 약물전달 시스템의 혁신은 신약의 기회를 생성합니다. 이 요인은 CNS 치료제 시장의 성장에 기여할 것으로 기대됩니다.

연구개발은 복잡한 프로세스이며, 제약 업계에서 중요한 결정입니다. 이것에는 신약의 안전성과 유효성의 상세연구와 이것을 시장에 출시하기 전의 규제 가이드라인의 준수가 포함됩니다. 또한 연구개발에 대한 지출은 항상 보다 높은 리턴을 가져온다고는 할 수 없으며, 제약기업이 CNS 치료제에 투자하는 것을 단념하게 할 가능성이 있습니다. 또한 항간질약 등의 특정 중추신경계약에 대해 보고되고 있는 부작용은 시장 전체의 성장을 저해할 가능성이 있습니다.

세계의 중추신경계 치료제 시장을 조사했으며, 시장의 개요, 시장 성장요인 및 저해요인 분석, 시장 기회, 지역별 시장 규모의 추이와 예측, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.


제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 촉진요인
    • 중추신경계 장애의 부담 상승
    • 제네릭 의약품의 증가
    • 신규 약물전달 시스템의 개발
  • 시장 억제요인
    • CNS 치료에 관련된 AE(ADVERSE EVENTS)
    • 높은 연구개발비
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 질병별
    • 신경혈관 질환
    • 트라우마
    • 정신건강
    • 변성질환
    • 감염증
    • 기타
  • 의약품 클래스별
    • 진통제
    • 신경계약
    • 마취제
    • 항파킨슨약
    • 항간질
    • 기타 의약품 클래스
  • 지역
    • 북미
    • 유럽
    • 아시아태평양
    • 중동과 아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Biogen
    • Otsuka Pharmaceutical Co. Ltd
    • Eli Lilly and Company
    • Merck KGaA
    • AstraZeneca
    • Takeda Pharmaceutical Coompany Limited
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Johnson &Johnson Private Limited
    • Pfizer Inc.
    • GlaxoSmithKline PLC

제7장 시장 기회 및 향후 전망

KSA 21.06.17

The central nervous system (CNS) therapeutics market is projected to register a CAGR of nearly 5.9% over the forecast period (2021 - 2026).

With the increasing COVID-19 cases, worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on central and peripheral systems. These included encephalopathy, inflammation, ischaemic stroke, and peripheral neurological disorders. A research study published in JAMA Neurology involving 214 patients in China showed that patients with severe illness from COVID-19 had neurologic manifestations of acute cerebrovascular disease, impaired consciousness, and skeletal muscle injury. Additionally, clinical trials on the repurposing of anti-depressants for COVID-19 may have minimal impact on the CNS therapeutics market.

An increase in the number of patients suffering from CNS disease is likely to be the key factor contributing to the growth of the CNS therapeutics market. According to the WHO, in 2019, stroke and Alzheimer's are the second and seventh top-most causes for deaths, globally. A study published in The Lancet finds that neurological diseases are the third common cause of disability and premature deaths and are estimated to increase with age in Europe. Additionally, a rise in generics is expected to drive the penetration of neurologic drugs to lower and middle-income countries, making them affordable. Along with this, increasing awareness programs may result in drugs being easily accessible. Innovation in drug delivery systems, such as nanoparticles, creates opportunities for new drugs. A recent Rutgers research in 2020 was conducted for the treatment of neurological disorders, by creating a micro-environment and suppressing inflammation using nanomaterials, polymers, and neural proteins. Therefore, all the above factors are expected to contribute to the growth of the CNS therapeutics market.

R&D is a complex process and an important decision within the pharmaceutical industry. It involves a detailed study of the safety and efficacy of novel drugs, along with meeting regulatory guidelines before releasing them into the market. According to the analysis by Tufts Center for the Study of Drug Development in 2018, CNS drug development is 20% more time-consuming and takes 38% longer time to get approved than other non-CNS drugs. Moreover, expenditure in R&D may not always yield higher returns, making it a risky investment. As a result, drugs are priced higher to recover the spending. Hence, risky R&D spending for developing CNS drugs may discourage pharmaceutical companies from investing in CNS therapeutics. Furthermore, adverse reactions reported for certain CNS drugs, such as anti-epileptic drugs, may inhibit the overall market growth.

Key Market Trends

Degenerative Disease is Expected to Dominate the CNS Therapeutics Market over the Forecast Period

The degenerative disease segment occupies a major share of the market over the forecast period (2021 - 2026). This disease occurs when nerve cells in the brain and peripheral nervous systems lose their function and die. The major share of it is attributed to the increasing prevalence of Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

According to the WHO, globally, 50 million people suffer from dementia, with nearly 60% living in low and middle-income countries. It estimates the number to reach 82 million by 2030. Atlas of MS shows that 2.8 million people live with multiple sclerosis worldwide and 10 million with Parkinson's disease as per the Parkinson's Foundation. The treatment options for these diseases are very few. Currently, five approved drugs are widely used for Alzheimer's, and 146 clinical studies are recruiting, which are in Phases 1, 2, and 3. Recently, FDA approved Ongentys capsules for Parkinson's disease when a patient's medications are not working well and Zeposia capsules for relapsing forms of multiple sclerosis. According to Alzheimer's Europe, it is estimated that about 7.8 million individuals in the European Union are with dementia. Furthermore, the Harvard NeuroDiscovery Center estimates that nearly 12 million Americans may suffer from neurodegenerative diseases 30 years from now if there are no measures taken. Therefore, the rise in prevalence of these diseases, drug development pipeline, and the potential of this segment opens opportunities for clinical studies, product launches, and strategic collaborations.

North America is Expected to Dominate the Central Nervous System Therapeutics Market

North America is expected to dominate the CNS therapeutics market over the forecast period (2021 - 2026).

According to GBD 2019, neurological disorders ranked third for the cause of deaths in Canada and fourth in the United States. The Alzheimer's Disease Fact and Figures Report estimated that 5.8 million Americans are living with dementia, among which 5.6 million are aged 65 years and above in 2019. The same source also reports that the total costs for Alzheimer's were USD 290 billion, which includes Medicare (51%), Medicaid (17%), Out of Pocket (22%), and other costs (11%).

Government funding and support for research activities are increasing due to the rising burden of the disease. The US congress invested about USD 10 million in multiple sclerosis research and may increase the funding by USD 20 million. CDC established a National Neurological Conditions Surveillance System (NNCSS) for tracking the disease. In 2019, Canada released its first national strategy for tackling dementia. The Canadian Institutes of Health Research spent around USD 200 million for research activities on dementia, and it is providing an additional USD 31.6 million over 5 years, which is likely to bring together individuals for advanced research opportunities. A large number of clinical studies are undergoing in North America, especially in the United States. Among the total neurological disease clinical studies being conducted, worldwide, more than half are in the United States. In March 2021, US President Biden signed the American Rescue Plan Act 2021. According to the act, a portion of spending is allotted to mental health services, further increasing the government activities toward neurological diseases. The rising burden of the disease and healthcare infrastructure and supportive government initiatives make North America a very attractive opportunity for industries.

Competitive Landscape

The central nervous system therapeutics market remains moderately competitive, with key players in the market. However, the need for innovation in the treatment and drug delivery system and clinical trials and strategic collaboration is likely to help companies maintain their market position. Some of the major players include Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck & Co., AstraZeneca, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, Pfizer Inc., and GlaxoSmithKline PLC.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Burden of CNS Disorders
    • 4.2.2 Increase in Generic Drugs
    • 4.2.3 Development of Novel Drug Delivery Systems
  • 4.3 Market Restraints
    • 4.3.1 Adverse Events Associated with CNS Therapeutics
    • 4.3.2 High R&D Costs
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Disease
    • 5.1.1 Neurovascular Diseases
    • 5.1.2 Trauma
    • 5.1.3 Mental Health
      • Anxiety Disorders
      • Epilepsy
      • Psychotic Disorders
      • Others
    • 5.1.4 Degenerative Diseases
      • Alzheimer's Disease
      • Parkinson's Disease
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Others
    • 5.1.5 Infectious Diseases
    • 5.1.6 Cancer
    • 5.1.7 Others
  • 5.2 By Drug Class
    • 5.2.1 Analgesics
    • 5.2.2 Nervous System Drugs
    • 5.2.3 Anesthetics
    • 5.2.4 Anti-Parkinson Drugs
    • 5.2.5 Anti-Epileptics
    • 5.2.6 Other Drug Classes
  • 5.3 By Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Biogen
    • 6.1.2 Otsuka Pharmaceutical Co. Ltd
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Merck KGaA
    • 6.1.5 AstraZeneca
    • 6.1.6 Takeda Pharmaceutical Coompany Limited
    • 6.1.7 Novartis AG
    • 6.1.8 Teva Pharmaceutical Industries Ltd
    • 6.1.9 Johnson & Johnson Private Limited
    • 6.1.10 Pfizer Inc.
    • 6.1.11 GlaxoSmithKline PLC


Back to Top
전화 문의